- Home
- EBMT vs IKT Comparison
EBMT vs IKT Comparison
Compare EBMT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- IKT
- Stock Information
- Founded
- EBMT 1922
- IKT 2008
- Country
- EBMT United States
- IKT United States
- Employees
- EBMT N/A
- IKT N/A
- Industry
- EBMT Major Banks
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EBMT Finance
- IKT Health Care
- Exchange
- EBMT Nasdaq
- IKT Nasdaq
- Market Cap
- EBMT 134.3M
- IKT 123.7M
- IPO Year
- EBMT N/A
- IKT 2020
- Fundamental
- Price
- EBMT $16.57
- IKT $1.70
- Analyst Decision
- EBMT
- IKT Buy
- Analyst Count
- EBMT 0
- IKT 2
- Target Price
- EBMT N/A
- IKT $8.00
- AVG Volume (30 Days)
- EBMT 20.4K
- IKT 109.6K
- Earning Date
- EBMT 10-28-2025
- IKT 11-14-2025
- Dividend Yield
- EBMT 3.53%
- IKT N/A
- EPS Growth
- EBMT 58.15
- IKT N/A
- EPS
- EBMT 1.72
- IKT N/A
- Revenue
- EBMT $87,531,000.00
- IKT N/A
- Revenue This Year
- EBMT N/A
- IKT N/A
- Revenue Next Year
- EBMT $5.45
- IKT N/A
- P/E Ratio
- EBMT $9.64
- IKT N/A
- Revenue Growth
- EBMT 9.36
- IKT N/A
- 52 Week Low
- EBMT $14.35
- IKT $1.33
- 52 Week High
- EBMT $18.49
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- EBMT 46.74
- IKT 59.79
- Support Level
- EBMT $16.12
- IKT $1.33
- Resistance Level
- EBMT $16.60
- IKT $1.76
- Average True Range (ATR)
- EBMT 0.30
- IKT 0.12
- MACD
- EBMT -0.02
- IKT 0.02
- Stochastic Oscillator
- EBMT 55.56
- IKT 86.05
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.